Vancouver, BC – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high… Read More
Aliada’s lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer’s disease Acquisition also allows AbbVie to utilize Aliada’s novel blood-brain barrier (BBB)-crossing technology… Read More
A genetic signature in newborns can predict neonatal sepsis before symptoms even start to show, according to a new study. The study, led by UBC and SFU researchers in collaboration… Read More
Six out of 10 infants and newborns in Canada will have access to the protective antibody Beyfortus® for the first time this season Access to Beyfortus® includes infants in remote communities most impacted by… Read More
Presentations highlight key preclinical data that support investigational new drug application (IND) submissions for ZW220 in 1H and ZW251 in 2H in 2025 VANCOUVER, BC – Zymeworks Inc. (Nasdaq: ZYME),… Read More
